FDA Approves Osimertinib as Adjuvant Therapy Following Resection of NSCLC with EGFR Mutations

Full approval has been granted by the FDA to osimertinib (Tagrisso) for use as adjuvant therapy following tumor resection among patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

The FDA has approved osimertinib (Tagrisso) as adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, according to an FDA press release.1

Efficacy of osimertinib was demonstrated in the randomized, double-blind, placebo-controlled, phase 3 ADAURA trial (NCT02511106), which evaluated patients with EGFR exon 19 deletion or exon 21 L858R mutation–positive NSCLC who had complete tumor resection with or without prior adjuvant chemotherapy.2 Patients with resectable tumors, defined as stage IB to IIIA, were deemed eligible for the study if they had predominantly nonsquamous histology and EGFR exon 19 deletions or exon 21 L858R mutations identified prospectively from tumor tissue in a central laboratory by the cobas EGFR Mutation Test.

The primary end point was disease-free survival (DFS) in patients with stage II to IIIA disease according to investigator assessment. Secondary end points included DFS in the overall population of patients with stage IB to IIIA disease, overall survival (OS), and safety.

Overall, 682 patients were randomized 1:1 to receive osimertinib at a dose of 80 mg orally once daily or placebo following recovery from surgery and standard adjuvant chemotherapy, if given.

At 24 months, 90% of the patients with stage II to IIIA disease in the osimertinib group (95% CI, 84%-93%) and 44% of those in the placebo group (95% CI, 37%-51%) were alive and free of disease (overall HR, 0.17; 99.06% CI, 0.11-0.26; P < .001). Median DFS was not reached (95% CI, 38.8-not calculable [NC]) in patients on the osimertinib arm compared with 19.6 months (95% CI, 16.6, 24.5) on the placebo arm.

Among the overall study population, 89% of the patients in the osimertinib group (95% CI, 85%-92%) and 52% of those in the placebo group (95% CI, 46%-58%) were alive and disease free at 24 months (overall HR, 0.20; 99.12% CI, 0.14-0.30; P < .001). Median DFS in the overall study population was also not reached (95% CI, NC-NC) in patients on osimertinib compared with 27.5 months (95% CI, 22-36) on the placebo arm.

Moreover, 98% of the patients in the osimertinib group (95% CI, 95%-99%) and 85% of those in the placebo group (95% CI, 80%-89%) were alive and did not have central nervous system disease at 24 months (overall HR, 0.18; 95% CI, 0.10 to 0.33).

OS data were immature; however, 29 patients had died (9 in the osimertinib group, 20 in the placebo group).

No new safety concerns were noted in the study. The most common (>20%) adverse events observed in patients taking osimertinib, including laboratory abnormalities, were lymphopenia, leukopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, neutropenia, dry skin, stomatitis, fatigue, and cough.

The FDA-recommended dose of osimertinib for adjuvant treatment of early-stage NSCLC is 80 mg orally once daily, with or without food, until disease recurrence or unacceptable toxicity or for up to 3 years.


1. FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations [news release]. Published December 18, 2020. Accessed December 18, 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations?utm_medium=email&utm_source=govdelivery

2. Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020;383(18):1711-1732. doi: 10.1056/NEJMoa2027071

Related Videos
An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.
Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non-small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Data from the phase 3 LUSTRE trial indicated that stereotactic body radiotherapy is a safe and effective alternative to conventional radiation for use in patients with stage I medically-inoperable non-small lung cancer, according to an expert from Juravinski Cancer Centre in Canada.
In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.
Experts on lung cancer
Related Content